BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17697491)

  • 21. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction.
    Balasch J; Peñarrubia J; Fábregues F; Vidal E; Casamitjana R; Manau D; Carmona F; Creus M; Vanrell JA
    Reprod Biomed Online; 2003; 7(1):35-42. PubMed ID: 12930572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
    Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
    Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study.
    Olgan S; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
    Kyrou D; Kolibianakis EM; Fatemi HM; Tarlatzis BC; Tournaye H; Devroey P
    Fertil Steril; 2011 Nov; 96(5):1112-5. PubMed ID: 21924414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI.
    Bjercke S; Tanbo T; Abyholm T; Omland A; Opøien HK; Fedorcsak P
    Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1053-60. PubMed ID: 20602599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical comparison of ovarian stimulation and luteal support agents in patients undergoing GnRH antagonist IVF cycles.
    Miller CE; Zbella E; Webster BW; Doody KJ; Bush MR; Collins MG
    J Reprod Med; 2013; 58(3-4):153-60. PubMed ID: 23539885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of HCG in IVF Treatment: Does it depend on age or on protocol?
    Theofanakis C; Athanasiou V; Liokari E; Stavrou S; Sakellariou M; Athanassiou AI; Athanassiou A; Drakakis P; Loutradis D
    J Gynecol Obstet Hum Reprod; 2019 May; 48(5):341-345. PubMed ID: 30794953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual Triggering With Gonadotropin-Releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate.
    Fabris AM; Cruz M; Legidos V; Iglesias C; Muñoz M; García-Velasco JA
    Reprod Sci; 2017 Aug; 24(8):1221-1225. PubMed ID: 28715965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of different ovarian stimulation protocols for in vitro fertilization.
    Pados G; Tarlatzis BC; Bontis J; Lagos S; Papadimas J; Spanos E; Mantalenakis S
    Gynecol Endocrinol; 1995 Jun; 9(2):103-12. PubMed ID: 7502685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Timing of HMG supplementation and clinical outcomes of advanced-age patients with diminished ovarian reserve receiving gonadotropin-releasing hormone antagonist protocol].
    Wu X; Chen Y; Zhou X; Zhang J; Li Y; Li X; Zhang X; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):412-417. PubMed ID: 33849833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective comparative study on IVF outcomes with either purified FSH or human menopausal gonadotrophin in downregulated normogonadotrophic women.
    Ismail AF; Hesham AI; Salah Z; Khaled M; Fouad N; Ashraf N; Hatem S; Hamdi B
    Gynecol Obstet Invest; 2002; 53(4):220-3. PubMed ID: 12186987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols.
    Orvieto R; Rabinson J; Meltzer S; Zohav E; Anteby E; Homburg R
    Reprod Biomed Online; 2006 Aug; 13(2):198-201. PubMed ID: 16895632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization.
    Daya S; Gunby J; Hughes EG; Collins JA; Sagle MA
    Hum Reprod; 1995 Jun; 10(6):1392-6. PubMed ID: 7593503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles.
    Seval MM; Özmen B; Atabekoğlu C; Şükür YE; Şimşir C; Kan Ö; Sönmezer M
    J Obstet Gynaecol Res; 2016 Sep; 42(9):1146-51. PubMed ID: 27199084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.